SciSparc (NASDAQ:SPRC) Stock Price Down 14.5% – Time to Sell?

SciSparc Ltd. (NASDAQ:SPRC)’s stock price traded down 14.5% during trading on Wednesday. The stock traded as low as $0.5068 and last traded at $0.5126. Approximately 226,750 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 4,215,168 shares. The stock had previously closed at $0.5994.

Analysts Set New Price Targets

SPRC has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a report on Friday, August 21st. Wall Street Zen upgraded SciSparc to a “hold” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, SciSparc presently has an average rating of “Sell”.

SciSparc Stock Down 14.5%

The business’s 50 day moving average is $3.80 and its 200-day moving average is $5.48.

SciSparc (NASDAQ:SPRC) last posted its quarterly earnings data on Friday, August 14th. The company reported ($4.85) earnings per share for the quarter. The business had revenue of $0.14 million for the quarter.

About SciSparc

SciSparc Ltd. (NASDAQ: SPRC) is an Israel-based clinical-stage specialty pharmaceutical company focused on developing therapies based on cannabinoid molecules. The company’s research is aimed primarily at central nervous system disorders and other conditions for which existing treatment options may be limited.

SciSparc’s pipeline has included investigational products such as SCI-110, a cannabinoid-based combination therapy being studied for conditions including Tourette syndrome and obstructive sleep apnea, as well as programs addressing Alzheimer’s disease agitation and pain.